Fig. 1: Proposed management recommendations for patients with newly diagnosed multiple myeloma and +1q21 by FISH.

V = bortezomib; R or Len = lenalidomide; d = dexamethasone; Dara or D = daratumumab; ASCT = autologous stem cell transplantation with high-dose melphalan conditioning; HR CA = high risk cytogenetic abnormalities. aCarfilzomib may be substituted for bortezomib if neuropathy is present.